Davis Capital Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Davis Capital Management's PTGX Position: Q3 2026 in Review
Davis Capital Management increased its Protagonist Therapeutics (PTGX) stake by 33% in Q3 2026, buying an estimated $143 and bringing the position to 4 shares worth $564. The position accounts for ﹤0.01% of the portfolio, ranked #608.
Davis Capital Management first reported a position in PTGX in Q2 2026 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Davis Capital Management held 4 shares of Protagonist Therapeutics worth $564 as of Q3 2026.
- Davis Capital Management bought 1 Protagonist Therapeutics share in Q3 2026, an estimated $143.
- Protagonist Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #608 holding.
- Davis Capital Management first reported a position in Protagonist Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.